课件：外科治疗缺血性心力衰竭SICH的研究概要.pptVIP

Canadian Cardiovascular Society Angina Class in Hypothesis 2 Patients at Baseline and Latest Follow-up Patients No Angina121 Class I-II130 Class III-IV248 No Angina339 Class I-II88 Class III-IV8 No Angina128 Class I-II129 Class III-IV244 No Angina339 Class I-II83 Class III-IV6 Angina symptoms improved by an average of 1.7 classes in both cohorts (P=0.84). New York Heart Association Heart Failure Class in Hypothesis 2 Patients at Baseline and Latest Follow-up Patients Class I 36 Class II222 Class III-IV241 Class I165 Class II190 Class III-IV80 Class I 50 Class II207 Class III-IV244 Class I179 Class II188 Class III-IV62 Heart failure symptoms improved by an average of one class In both cohorts (P = 0.70). Baseline and Four Month 6-Minute Walk in 693 Hypothesis 2 Patients with Baseline Assessment Patients 30-Day Mortality Outcome CABG N = 499 CABG + SVR N = 501 P Death Within 30 Days After Randomization All patients by intention to treat 22/499 (4.4%) 30/501 (6.0%) 0.26 Death During or Within 30 Days of Operation Operated patients by intention to treat 25/490 (5.1%) 26/489 (5.3%) 0.88 Operated patients by operation received 23/498 (4.6%) 28/481 (5.8%) 0.40 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0 1 2 3 4 5 Event Rate Years from Randomization CABG 499 501 319 319 270 275 220 216 99 11 23 23 CABG CABG+SVR No. at Risk Death or Cardiac Hospitalization  Kaplan-Meier Estimates of Primary Endpoint 292 events 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0 1 2 3 4 5 Event Rate Years from Randomization CABG CABG+SVR HR 0.99 (95% CI: 0.84, 1.17), P=0.90 499 501 319 319 270 275 220 216 99 11 23 23 CABG CABG+SVR No. at Risk Death or Cardiac Hospitalization Kaplan-Meier Estimates of Primary Endpoint 292 events 289 events Mortality (All-Cause) Kaplan-Meier Estimates 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0 1 2 3 4 5 Mortality Rate Years from Randomization CABG 499 501